Myomatrix Therapeutics LLC
This article was originally published in Start Up
Executive Summary
Myomatrix is the creation of a heart transplant cardiologist with a mission of preventing his patients from developing transplant vasculopathy, the most common cause of late heart graft loss a year or more after a heart transplant operation. But the start-up's kinase inhibitors have application to much larger diseases as well, including congestive heart failure and angina.